IceCure Medical Reports Record 2025 ProSense® Sales Driven by Strong US Demand Post-FDA Authorization

summarizeSummary

IceCure Medical announced record preliminary 2025 ProSense® sales of $3.4 million, fueled by strong U.S. demand following its FDA marketing authorization for low-risk breast cancer, alongside a healthy cash balance and positive 2026 outlook.

check_boxKey Events · Earnings and Guidance · ICCM

• Record 2025 ProSense® Sales

  Preliminary, unaudited sales reached approximately $3.4 million for the full year 2025, marking a record for the company's ProSense® system.

• Strong U.S. Demand Post-FDA Authorization

  Sales were significantly boosted by strong demand in the U.S. following the October 2025 FDA marketing authorization for ProSense® in low-risk breast cancer.

• Significant Market Opportunity

  ProSense® addresses an estimated 200,000 U.S. patients annually for breast cryoablation, indicating a substantial growth runway.

• Healthy Cash Position

  The company reported approximately $8.9 million in cash and cash equivalents as of December 31, 2025.

auto_awesomeAnalysis · ICCM · Industrial Applications And Services

IceCure Medical's preliminary 2025 sales figures indicate significant commercial traction for its ProSense® system, particularly in the U.S. market. The record sales, directly attributed to the recent FDA marketing authorization for low-risk breast cancer, highlight the product's growing adoption and the company's ability to capitalize on a substantial addressable patient population. The healthy cash position provides a solid foundation for continued operations and planned expansion. Investors should monitor the company's progress on 2026 objectives, including further reimbursement coverage and international regulatory approvals, as these could sustain the positive momentum.